Recently, Jinshi Pharmaceutical announced that one of its subsidiaries has successfully obtained the ‘High-Tech Enterprise’ certification issued by relevant national authorities. This recognition not only affirms the company’s strong capabilities in R&D innovation, technological expertise, and commercialization of scientific achievements, but also signifies tangible progress resulting from its sustained investment in the pharmaceutical and healthcare sector.According to China’s ‘Administrative Measures for High-Tech Enterprise Recognition,’ certified enterprises must meet stringent criteria regarding core intellectual property ownership, R&D expenditure as a percentage of revenue, proportion of technical personnel, and income derived from high-tech products. Jinshi Pharmaceutical’s subsidiary passed the evaluation based on its notable achievements in modernizing traditional Chinese medicine, developing novel drug formulations, and implementing smart manufacturing technologies. As a result, the subsidiary will benefit from a preferential 15% corporate income tax rate—significantly lower than the standard 25%—for the next three years, along with enhanced access to government-funded research programs and supportive policies.As a company dedicated to the integrated research, development, manufacturing, and sales of traditional Chinese medicines, chemical drugs, and health products, Jinshi Pharmaceutical has consistently increased its R&D investment in recent years to bridge traditional Chinese medicine with modern science and technology. This certification not only enhances the company’s technological reputation but also lays a solid foundation for expanding its high-value product portfolio and strengthening market competitiveness.
近日，金石亚药（Jinshi Yayao）宣布其子公司成功获得由国家相关部门颁发的‘高新技术企业’证书。这一认证不仅是对该公司在研发创新、技术实力和科技成果转化能力方面的高度认可，也标志着其在医药健康领域的持续投入取得了实质性成果。根据中国《高新技术企业认定管理办法》，获得该资质的企业需在核心技术自主知识产权、研发投入占比、科技人员比例以及高新技术产品收入等方面达到严格标准。金石亚药子公司凭借在中药现代化、新型制剂开发及智能制造等方向的突出表现，顺利通过评审。获得该证书后，企业将在未来三年内享受15%的企业所得税优惠税率（低于一般企业的25%），并有望获得更多政府科研项目支持与政策倾斜。作为一家专注于中成药、化学药及健康产品研产销一体化的企业，金石亚药近年来持续加大科研投入，推动传统中医药与现代科技融合。此次子公司获高新技术企业认定，不仅提升了公司整体技术形象，也为未来拓展高附加值产品线、增强市场竞争力奠定了坚实基础。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/15759.html